Advertisement

Martin J. Edelman, MD, Joins Fox Chase Cancer Center as Chair of the Department of Hematology/Oncology


Martin J. Edelman, MD

Martin J. Edelman, MD

Martin J. Edelman, MD, an expert in the research and treatment of lung cancer, has joined Fox Chase Cancer Center, Philadelphia, as Chair of the Department of Hematology/Oncology. He will also serve as Deputy Cancer Center Director for Clinical Research, leading the effort to integrate discoveries from the Translational Research Initiative into a strong, investigator-initiated clinical trials program.

Dr. Edelman will collaborate with clinical, scientific, and administrative leadership to grow robust therapeutic, clinical research, and translational research programs in hematology and medical oncology, while leading the department in the evaluation of emerging national trends in the delivery of cancer care.

“Dr. Edelman is a visionary in his field, and I am confident he will lead our Department of Hematology/Oncology to even greater heights,” said Richard I. Fisher, MD, President and CEO of Fox Chase. “I am delighted that he has chosen to become a key part of our faculty, and I look forward to what we will all achieve together in the coming years.”

“Fox Chase Cancer Center has a national and international reputation for excellence,” Dr. Edelman said. “I look forward to working with leading experts in cancer research and treatment, as we continue the institution’s long legacy of progress against cancer.”

Dr. Edelman comes to Fox Chase from the University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, where he served most recently as Head of the Section of Solid Tumor Oncology and Associate Director of the Division of Hematology/Oncology. In addition, he was Professor of Medicine and Radiation Oncology at the University of Maryland School of Medicine.

Activities and Achievements

After receiving his medical degree from Albany Medical College, Dr. ­Edelman completed his residency training in internal medicine and a hematology/oncology fellowship at the Naval Hospital in San Diego. He served for more than 20 years in the U.S. Navy Reserve, retiring with the rank of Captain. During his active service, Dr. Edelman served aboard the USS Duluth as Senior Medical Officer, providing care to 1,000 Navy and Marine personnel.

Dr. Edelman’s achievements in oncology include developing one of the most commonly used regimens for treating advanced lung cancer and working toward the development of new agents and biomarkers to personalize lung cancer therapy. He has a particular interest in approaches that integrate surgery, radiation, and chemotherapy in the management of patients with lung cancer.

He serves on the Lung Cancer Committee of the Alliance for Clinical Trials in Oncology (previously, Cancer and Leukemia Group B), the Board of Directors of the Alliance, and the Thoracic Malignancies Steering Committee of the National Cancer Institute’s Scientific Review Group. In addition, he is Medical Oncology Co-Chair for the Lung Cancer Committee of the Radiation Therapy Oncology Group (now part of NRG Oncology).

Dr. Edelman has been active within ASCO and has chaired the lung cancer sections for the Scientific and Educational Committees, as well as served as a past member of the Governmental Affairs Committee. As a member of the International Association for the Study of Lung Cancer, he has chaired the Career Development and Ethics Committees.

In addition to clinical and leadership achievements, Dr. Edelman has served on the editorial boards or as an ad hoc reviewer of numerous academic journals, including The New England Journal of Medicine and the Journal of Clinical Oncology, and currently serves as Deputy Editor of Lung Cancer. ■



Advertisement

Advertisement



Advertisement

click me